Strategies & Technologies Driving Drug Discovery to Market
Live Last read · last published · next check
The demand for peptide therapeutics has grown rapidly in recent years, as the success of GLP-1 drugs has catapulted them to the forefront of developers’ and sponsors’ minds. Although peptides still represent a relatively small share of FDA-approved therapeutics, they offer distinct advantages in treating diseases where small-molecule drugs or therapeutic antibodies fall short. The… The post…
2022 was a big year for layoffs in biopharma. So were the next three. Novartis, for instance, outlined plans to cut up to 8,000 jobs in 2022, after pharmaceutical industry job cuts jumped 280% in 2021. Biogen followed in 2023 with a “Fit for Growth” program that put roughly 1,000 roles on the block. Bristol… The post As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%…
OpenAI’s first international hospital partnership is taking shape at a giant medical center where English is not the default language and where the electronic health record does not come from Epic, the dominant U.S. EHR vendor. That institution is Sheba Medical Center, the Israel-based medical center with its own 50-plus-person AI Center within ARC, its… The post How Sheba Medical Center became…
The FDA has finalized new guidelines for meetings between the FDA and sponsors or applicants relating to the development and review of drugs or biological products under the Prescription Drug User Fee Act (PDUFA). The FDA first published the draft guidance on Sept. 22, 2023, when it collected public comment on the guidelines. The final guidelines contain several changes from the draft, including…
Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward tumor cells. The class now spans about 15 FDA-approved products, and the segment is growing steadily. Evaluate Pharma projects the ADC category will reach $57… The post Gilead and Nucleai probe why…
The 1990-founded scientific software firm Schrödinger recently announced a strategic collaboration and software agreement with Bristol Myers Squibb (BMS) built around Bunsen, Schrödinger’s newly announced agentic AI co-scientist. While the term “AI co-scientist” can have varying definitions, Schrödinger is positioning Bunsen as a sort of execution engine for computational chemistry, including…
By one measure, Alphabet-controlled Isomorphic Labs would tower over every company on this list. The AI drug discovery company has raised $2.7 billion in external financing, including a $2.1 billion Series B announced in May. Its corporate structure, however, puts it outside our definition of an independent biotech startup: Alphabet still controls at least 75%… The post The 50 best-funded biotech…
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of… The…
The Department of Health and Human Services (HHS) is soliciting nominations for appointment to the National Vaccine Advisory Committee (NVAC), the agency said in a notice published Wednesday. A renewed NVAC charter filed in July estimates the committee’s annual operating cost at $756,918 and calls for staff support equivalent to two full-time employees. The committee has not met since September…
Novo Nordisk’s ziltivekimab, an investigational human monoclonal antibody that targets the IL-6 ligand, a pro-inflammatory cytokine, to reduce cardiovascular inflammation, did not reduce the risk of major adverse cardiovascular events (MACE) in a Phase 3 trial. “Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population,” Martin Holst…
